Evidence map›Paper›PMID 37652502›Full record

Observational studyIn vivo (Athens, Greece)

Atezolizumab Monotherapy for Non-small Cell Lung Cancer Patients: An Observational Study in Ibaraki Group (ATTENTION-IBARAKI).

Shinichiro Okauchi, Gen Ohara, Toshihiro Shiozawa, Hiroko Watanabe, Takeshi Numata, Ryota Nakamura, Tomohiro Tamura, Norihiro Kikuchi, Kunihiko Miyazaki, Shigen Hayashi and 10 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Shinichiro OkauchiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Gen OharaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Toshihiro ShiozawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroko WatanabeDivision of Respiratory Medicine, Tsukuba Memorial Hospital, Tsukuba, Japan.
Takeshi NumataDepartments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
Ryota NakamuraDepartments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan.
Tomohiro TamuraRespiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Norihiro KikuchiDivision of Respiratory Medicine, National Hospital Organization Kasumigaura Medical Center, Tsuchiura, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Shigen HayashiDivision of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan.
Hirofumi SakuraiDivision of Respiratory Medicine, Ibaraki Seinan Medical Center Hospital, Sakai, Japan.
Takaaki YamashitaDivision of Respiratory Medicine, JA Toride Medical Center Hospital, Toride, Japan.
Koichi KurishimaDivision of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Japan.
Masaharu InagakiDivision of Thoracic Surgery, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan.
Takeo EndoDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Hiroichi IshikawaDivision of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Japan.
Takayuki KaburagiRespiratory Center, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Hiroaki SatohDepartments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan; hirosato@md.tsukuba.ac.jp.
Toru SakamotoDivision of Respiratory Medicine, Tsukuba Memorial Hospital, Tsukuba, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAtezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1) expressed on cancer cells derived from various organs and antigen-presenting cells and is currently commonly used in combination with chemotherapy. We conducted a study to clarify the current status of response to atezolizumab monotherapy in clinical practice and clarify the factors that contribute to long-term response and survival. PATIENTS AND

methodsWe conducted a retrospective review of patients with advanced non-small cell lung cancer (NSCLC) treated with atezolizumab monotherapy from April 2018 to March 2023 at 11 Hospitals.

resultsThe 147 patients evaluated had a progression-free survival (PFS) of 3.0 months and an overall survival of 7.0 months. Immune-related adverse events of any grade were observed in 13 patients (8.8%), grade 3 or higher in nine patients (6.1%), and grade 5 with pulmonary toxicity in one patient (0.7%). Favorable factors related to PFS were 'types of NSCLC other than adenocarcinoma'. Favorable factors for overall survival were 'performance status 0-1' and 'treatment lines up to 3'. There were 16 patients (10.9%) with PFS >1 year. No characteristic clinical findings were found in these 16 patients compared to the remaining 131 patients.

conclusionEfficacy and immune-related adverse events of NSCLC patients associated with atezolizumab monotherapy were comparable to those of previous clinical trial results. Knowledge of characteristics of patients who are most likely to benefit from atezolizumab monotherapy is a crucial step towards implementing appropriate prescribing.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenAtezolizumabchemotherapyimmune-related adverse eventsoverall survivalprogression-free survival

Identifiers

PMID37652502
PMCPMC10500511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.